Nishanth Ulhas Nair
Overview
Explore the profile of Nishanth Ulhas Nair including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li H, Furusawa T, Cavero R, Xiao Y, Chari R, Wu X, et al.
Redox Biol
. 2025 Jan;
80:103503.
PMID: 39854937
Metabolic pathways fuel tumor progression and resistance to stress conditions including chemotherapeutic drugs, such as DNA damage response (DDR) inhibitors. Yet, significant gaps persist in how metabolic pathways confer resistance...
2.
Sanghvi N, Calvo-Alcaniz C, Rajagopal P, Scalera S, Canu V, Sinha S, et al.
Sci Adv
. 2024 Dec;
10(49):eadn0220.
PMID: 39642223
Metastasis is a leading cause of cancer-related deaths, yet understanding how metastatic tumors adapt from their origin to their target tissues remains a fundamental challenge. To address this, we assessed...
3.
Mir S, Venugopalan A, Zhang J, Nair N, Sengupta M, Khanal M, et al.
Clin Transl Med
. 2024 Nov;
14(11):e70057.
PMID: 39548594
Patients with advanced gastric and colorectal cancers have limited treatment options. Since mesothelin is highly expressed in these tumour types, we evaluated the therapeutic benefits of anti-mesothelin hYP218 CAR T...
4.
Nair N, Schaffer A, Gertz E, Cheng K, Zerbib J, Sahu A, et al.
Cancer Res
. 2024 Jul;
84(20):3464-3477.
PMID: 39078448
The co-occurrence of chromosome 10 loss and chromosome 7 gain in gliomas is the most frequent loss-gain co-aneuploidy pair in human cancers. This phenomenon has been investigated since the late...
5.
Sinha S, Vegesna R, Mukherjee S, Kammula A, Dhruba S, Wu W, et al.
Nat Cancer
. 2024 Apr;
5(6):938-952.
PMID: 38637658
Tailoring optimal treatment for individual cancer patients remains a significant challenge. To address this issue, we developed PERCEPTION (PERsonalized Single-Cell Expression-Based Planning for Treatments In ONcology), a precision oncology computational...
6.
Nair N, Schaffer A, Gertz E, Cheng K, Zerbib J, Sahu A, et al.
bioRxiv
. 2024 Feb;
PMID: 38313282
The co-occurrence of chromosome 10 loss and chromosome 7 gain in gliomas is the most frequent loss-gain co-aneuploidy pair in human cancers, a phenomenon that has been investigated without resolution...
7.
Sanghvi N, Calvo-Alcaniz C, Rajagopal P, Scalera S, Canu V, Sinha S, et al.
bioRxiv
. 2023 Dec;
PMID: 38076973
Metastasis is a leading cause of cancer-related deaths, yet understanding how metastatic tumors adapt from their origin to target tissues is challenging. To address this, we assessed whether primary and...
8.
Nair N, Greninger P, Zhang X, Friedman A, Amzallag A, Cortez E, et al.
Nat Commun
. 2023 Jun;
14(1):3830.
PMID: 37380628
Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited efficacy of single agents. The design and testing of combinations are however very challenging. Here we present...
9.
Nair N, Jiang Q, Wei J, Misra V, Morrow B, Kesserwan C, et al.
Cell Rep Med
. 2023 Feb;
4(2):100938.
PMID: 36773602
Malignant mesothelioma is an aggressive cancer with limited treatment options and poor prognosis. A better understanding of mesothelioma genomics and transcriptomics could advance therapies. Here, we present a mesothelioma cohort...
10.
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Sahu A, Wang X, Munson P, Klomp J, Wang X, Gu S, et al.
Cancer Discov
. 2023 Feb;
13(3):672-701.
PMID: 36745048
Significance: BipotentR presents resources for evaluating patient response and identifying targets for drugs that can kill tumors through multiple mechanisms concurrently. Inhibition of the topmost candidate target killed tumors by...